Sage Therapeutics to Present at BMO 2020 Growth & ESG Conference
CAMBRIDGE, Mass.–(BUSINESS WIRE)–
Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at the BMO 2020 Growth & ESG Conference on Wednesday, December 9, 2020 at 3:00 p.m. ET.
A live webcast of the presentation can be accessed on the investor page of Sage’s website at investor.sagerx.com. A replay of the webcast will also be archived for up to 30 days on Sage’s website following the conference.
About Sage Therapeutics
Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health, and our depression, neurology and neuropsychiatry franchise programs aim to change how brain disorders are thought about and treated. Our mission is to make medicines that matter so people can get better, sooner. For more information, please visit www.sagerx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201203005946/en/
Investor Contact
Jeff Boyle
617-949-4256
[email protected]
Media Contact
Maureen L. Suda
617-949-4289
[email protected]
KEYWORDS: Massachusetts United States North America
INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health
MEDIA:
Logo |